Menu
The joint statement on RDI funding from the Academy of Finland Flagship projects
iCAN supports the joint statement on RDI funding from the Academy of Finland Flagship projects. The recent long-term funding plan for RDI (March 2023) is a significant step for Finland’s competitiveness…
The figure shows homologous recombination repair marker, RAD51 (red), in high-grade serous ovarian cancer tumor cell nuclei (blue).
New tool for tailoring drug treatment in ovarian cancer
Researchers at the Universities of Helsinki and Turku have developed a test to identify those ovarian cancer patients who benefit from traditional platinum-based chemotherapy as well as from a newer…
Exciting R2B funding news
iCAN had a strong showing in Business Finland’s last Research to Business funding round. Four out of eight projects funded at the University of Helsinki were from the iCAN community,…